The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Uveitis: Know the Risk Factors, Symptoms & Treatment Options

Uveitis: Know the Risk Factors, Symptoms & Treatment Options

October 22, 2018 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The effects of uveitis are life changing, causing vision damage and even blindness. However, early detection and effective treatment can halt inflammation and protect patients from permanent eye damage and vision loss.

You Might Also Like
  • Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Psoriatic Disease Linked to Higher Risk of Uveitis & Vice Versa
Also By This Author
  • New Clinical Insights into the Pathogenesis, Diagnosis & Treatment of Calcium Pyrophosphate Arthritis

This form of inflammation affects the middle layer of the eye wall, known as the uvea, and is a frequent complication of juvenile idiopathic arthritis (JIA). Idiopathic uveitis may also be diagnosed when no arthritis or other identifiable causes are present.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Uveitis is a complication of JIA about which both pediatric and adult rheumatologists must be aware and refer patients for regular screening eye exams,” says Kathleen O’Neil, MD.

As chief of the division of rheumatology and professor of clinical pediatrics at the Indiana University School of Medicine, Dr. O’Neil sees the importance of detecting all forms of pediatric uveitis early and engaging in close collaboration with a patient’s ophthalmologist to coordinate the best treatment, including systemic immunosuppressive therapies when needed to prevent permanent damage.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

She also cautions that uveitis is not only a pediatric concern. “Adult rheumatologists need to be aware of uveitis as a complication of JIA, especially for young adult patients transitioning from pediatric care who may never have had uveitis before, so have stopped routine screening exams. Uveitis can occur for the first time in adulthood.”

To improve uveitis awareness, Dr. O’Neil suggests all rheumatologists have a clear understanding of uveitis risk factors, symptoms and the best treatment options based on long-standing and emerging evidence.

The Risk Factors
Several factors put JIA patients at a higher risk for uveitis. These include the onset of arthritis at an early age, being female and having inflammation of four or fewer joints (i.e., oligoarticular JIA). A positive antinuclear antibody (ANA) test and being African-American or Asian are also risk factors, as well as certain genetic markers (HLA-B27, HLA-DR5 haplotype, HLA-DRB1*1104 allele, and a combination of HLA-DRB1*1104 and HLA-DPB1*0201 alleles).1,2

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The Symptoms
The chronic uveitis associated with JIA is usually asymptomatic. In the seronegative spondyloarthropathies, acute uveitis may occur. Common symptoms associated with acute uveitis include eye pain, erythema and photophobia.

“Children with the asymptomatic chronic uveitis may present with vision troubles by putting their face inches from a coloring page they are working on or standing very close to the television. They may also bump into things when they walk and exhibit other signs of visual difficulty,” Dr. O’Neil says. The child with HLA-B27-associated enthesitis-related arthritis (seronegative spondyloarthropathy) may occasionally develop red eye, indicating acute anterior uveitis. These patients are often photophobic. Usually, short-term topical treatment, such as steroid eye drops, controls this form of uveitis.

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: eye, Eye disease, Uveitis, vision

You Might Also Like:
  • Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Psoriatic Disease Linked to Higher Risk of Uveitis & Vice Versa
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)